

Subject city, state	Effective date	Subject city, state	Effective date
Overland Park, KS		Syracuse, NY	
Schnoor, Tami S	05/20/2002	Wilhelm, Melissa J	05/20/2002
Kansas City, MO		Chicago, IL	
Schoenhoeft, Joseph	05/20/2002	Williams, Vickie E	05/20/2002
Susanville, CA		Alton, IL	
Sefter, Anne H	05/20/2002	Wilson, Andrea	05/20/2002
Appomattox, VA		Acra, NY	
Shadrick, Lisa B	05/20/2002	Witter, Deborah Sue	05/20/2002
Salt Lake City, UT		Mesa, AZ	
Shaffer Beard, Debra Michelle	05/20/2002	Woodruff, Holly Lynn Fabricus	05/20/2002
Oklahoma City, OK		Gering, NE	
Shodeinde, Diana F	05/20/2002	Wright, Cecelia R	05/20/2002
Corona, CA		Chicago, IL	
Silfies, Jayne	05/20/2002	Wyatt-Riley, Sharon L	05/20/2002
Waynesburg, PA		Princeton, IN	
Soukup, Richard A	05/20/2002	Yates, Debra Lynne	05/20/2002
Riverside, IA		Costa Mesa, CA	
Sporn, Alexander L	05/20/2002	Yavel, Robert Paul	05/20/2002
Rego Park, NY		Jamaica, NY	
Stacy, Daniel Franklin	05/20/2002	Yemat, Alex Alberto	05/20/2002
Coronado, CA		Miami, FL	
Stanford, Samuel R	05/20/2002	Young, Hui Kim	05/20/2002
Midlothian, VA		Alcoa, TN	
Staple, Andrea Read	05/20/2002		
San Bernadino, CA			
Stapley, Susan Ilene Buchanan	05/20/2002		
Atascadero, CA			
Stephenson, Melanie Ann	05/20/2002		
Gallipolis, OH			
Stevens, Ami Rosemarie	05/20/2002		
Zanesville, OH			
Suliveres, Sara-Jane	05/20/2002		
St Johnsbury, VT			
Sutherland Ebel, Amy Jo	05/20/2002		
Enid, OK			
Thomas, Adriese	05/20/2002		
Chicago, IL			
Tilghman, James E	05/20/2002		
Cape Girardeau, MO			
Tillery, Merlene	05/20/2002		
E St Louis, IL			
Torres, Wilhelmina C	05/20/2002		
Oak Lawn, IL			
Travelstead-Russell, Lorie A	05/20/2002		
Galatia, IL			
Tummillo, Marie E	05/20/2002		
Manakin Sabot, VA			
Turner, John Melton	05/20/2002		
Menlo Park, CA			
Ty, Blandina F	05/20/2002		
Closter, NJ			
Vangraefschepe, Laurie June ..	05/20/2002		
Billings, MT			
Vespe, John Robert	05/20/2002		
Phoenix, AZ			
Visacki, Miodrag	05/20/2002		
Sarasota, FL			
Volpez, Pablo Enriquez	05/20/2002		
Oakland, CA			
Vu, Hong T	05/20/2002		
Chicago, IL			
Watson, Lesa	05/20/2002		
Shreveport, LA			
Wechling, Clare Deane	05/20/2002		
O'Fallon, MO			
Weremeichik, Jessica L	05/20/2002		
S Burlington, VT			
Wexler, Harold Mark	05/20/2002		
Chatsworth, CA			
White, Tracy Lyons	05/20/2002		
Phoenix, AZ			
White, Karrey Lee Stone	05/20/2002		
Meridian, ID			
Wilber, Harold	05/20/2002		

Dated: May 15, 2002.

Calvin Anderson, Jr.,*Director, Health Care Administrative
Sanctions, Office of Inspector General.*

[FR Doc. 02-13051 Filed 5-23-02; 8:45 am]

BILLING CODE 4150-04-P**DEPARTMENT OF HEALTH AND
HUMAN SERVICES****National Institutes of Health****Office of Biotechnology Activities
(OBA); Recombinant DNA Research:
Notice Under the NIH Guidelines****AGENCY:** National Institutes of Health
(NIH), PHS, DHHS.**ACTION:** Notice.

SUMMARY: The NIH is announcing that Appendix M-I-C-3 and Appendix M-I-C-4 of the *NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)* became effective on January 24, 2002, the date of OMB approval of those information collection requirements. Also, the NIH is correcting the date for filing annual reports with the NIH, per Appendix M-I-C-3, to be within 60 days of the anniversary date that the IND went into effect. Finally, notice is given that a new version of the *NIH Guidelines* is available on the OBA Web site, which includes these changes as well as other non-substantive corrections, updates, and navigational enhancements.

FOR FURTHER INFORMATION CONTACT:

Allan C. Shipp, NIH Office of Biotechnology Activities by phone at 301-435-2152, by e-mail at shippa@od.nih.gov, or by mail at NIH OBA, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892-7985.

SUPPLEMENTARY INFORMATION: On November 19, 2001, NIH OBA published a notice of amendments to the *NIH Guidelines* in the **Federal Register** (66 FR 57970). Those amendments became effective on December 19, 2001, except for the amendments to Appendix M-I-C-3 (Annual Reports) and Appendix M-I-C-4 (Safety Reporting), which were published for public comment to OMB regarding the paperwork burden of those information collection requirements. It was stated that those Appendices would take effect upon OMB approval. That approval was given on January 24, 2002.

Further, Appendix M-I-C-3 as published in the **Federal Register** on November 19, 2001 (66 FR 57970, specifically 57975), stated that the annual report to OBA is to be filed within 60 days of the date that the IND

was filed. Appendix M-I-C-3 has been corrected to state that annual reports are to be filed with OBA at the same time that they are filed with the Food and Drug Administration (FDA)—within 60 days of the anniversary of the date the IND went into effect. This filing requirement becomes effective with respect to the first annual safety report filed after January 24, 2002.

Other minor, non-substantive changes have been made to the *NIH Guidelines*, as warranted. In addition, for ease in navigating the document, the *NIH Guidelines* have been fully indexed. The electronic version includes hyperlinks from the index to relevant portions of the body of the document. Thus, when users identify a section of interest in the index, by simply clicking on the title of that section, they will be immediately brought to the corresponding portion of the *NIH Guidelines*.

All of these changes are listed in detail in a Summary of Amendments and Corrections that can be accessed, along with the new version of the *NIH Guidelines*, at: <http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html>.

Dated: May 17, 2002.

Ruth L. Kirschstein,

Acting Director, National Institutes of Health.
[FR Doc. 02-13057 Filed 5-23-02; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program (NTP); Availability of Data From Preliminary Studies and Proposed Study Protocols for Cancer Bioassays of Hexavalent Chromium in Rats and Mice; Request for Public Comment and Notice of Public Meeting

Summary

Hexavalent chromium (CAS number 18540-29-9) was nominated to the NTP for study of its potential toxicity and carcinogenicity when administered to animals in drinking water (see **Federal Register**: May 7, 2001, Vol. 66, No. 88, pages 23037-23039). Members of the California legislative delegation, the California Environmental Protection Agency, and the California Health and Human Services Agency nominated hexavalent chromium to the NTP for study. The basis for the nomination is a document prepared by the California Environmental Protection Agency's (EPA) Office of Environmental Health Hazard Assessment titled "Public Health Goal for Chromium in Drinking

Water", a copy of which is available on the NTP's Web site <http://ntp-server.niehs.nih.gov> (see NTP Studies of Hexavalent Chromium Compounds under What's New?).

The purpose of this notice is to announce:

(1) The availability of data from studies designed to assess the absorption of chromium by rats, mice and guinea pigs receiving hexavalent chromium, as sodium dichromate dihydrate, in drinking water;

(2) The design and availability of data from 90-day oral toxicity studies in rats and mice receiving hexavalent chromium in drinking water;

(3) A proposed design for 2-year rodent cancer studies of hexavalent chromium in drinking water;

(4) A public meeting to discuss these data and the proposed design for 2-year studies; and

(5) A request for public comments on these data and the proposed design for the 2-year studies.

Public Meeting

A public meeting will be held July 24, 2002 in the Rodbell Auditorium, Rall Building, South Campus, National Institute of Environmental Health Sciences (NIEHS), 111 T.W. Alexander Drive, Research Triangle Park, North Carolina. The meeting will begin at 8:30 AM and is open to the public.

Attendance at this meeting is limited only by the space available. Individuals who plan to attend are asked to register with the NTP executive secretary (see contact information below). The names of those registered to attend will be given to the NIEHS Security Office in order to gain access to the campus. Persons attending who have not pre-registered may be asked to provide pertinent information about the meeting, *i.e.*, title or host of meeting before gaining access to the campus. All visitors will need to be prepared to show 2 forms of identification (ID), *i.e.*, driver's license and one of the following: company ID, government ID, or university ID. Also those planning to attend who need special assistance are asked to notify the NTP executive secretary in advance of the meeting (see contact information below).

A tentative agenda is provided below and includes opportunity for oral public comment. A scientific panel of experts ("the Panel") will discuss the data, to date, obtained from NTP studies of hexavalent chromium administered as sodium dichromate dihydrate and the proposed study design for 2-year rodent cancer studies (see below, NTP Studies). The agenda and roster of the Panel will be available prior to the meeting on the

NTP Web site (<http://ntp-server.niehs.nih.gov>) and upon request to the executive secretary at the address given below. Following the meeting, summary minutes will be available electronically on the NTP Web site and in hardcopy upon request to the executive secretary.

Tentative Agenda

8:30 AM

Welcome and introductions

8:40 AM

Overview of the NTP

Hexavalent chromium nomination

NTP studies on hexavalent chromium

Proposed design for 2-year studies

Public comments

Noon

Lunch

1:00 PM

Presentation of remarks by scientific expert panel

General discussion

3:30 PM

Adjourn

Request for Public Comment

The NTP meeting on hexavalent chromium is open to the public and public comment is welcome on the data from the 21-day and 90-day studies, the proposed NTP 2-year study plans, and any other issues related to the evaluation of the toxicity and carcinogenicity of hexavalent chromium in drinking water. Time will be provided at the meeting for oral public comments and persons requesting time for an oral presentation are asked to contact the NTP Executive Secretary Dr. Mary S. Wolfe, (P.O. Box 12233, MD A3-01, Research Triangle Park, NC 27709, phone: 919-541-0530, fax: 919-541-0295, e-mail:

liaison@starbase.niehs.nih.gov). Persons registering to make oral comments are asked to provide contact information, including name, affiliation, mailing address, phone, fax, e-mail, and supporting organization (if any). Each speaker is also asked to provide, if possible, a written copy of the statement by July 15, 2002, to enable review by the Panel and NTP staff prior to the meeting. The written statement can supplement and may expand the oral presentation. At least seven minutes will be allotted to each speaker, and if time permits, may be extended to ten minutes. Each organization is allowed one time slot for an oral presentation. Registration for making public comments will also be available on-site. If registering on-site to speak and reading comments from printed copy, the speaker is asked to provide 15 copies of the statement. These copies